ReviewAmerican journal of physiology. Gastrointestinal and liver physiology2019
Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.
Review in American journal of physiology. Gastrointestinal and liver physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05465642 (Alterations of Gut Microbiota and Serum Biochemical Markers in Asian Patients With Drug-induced Liver Injury), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alterations of Gut Microbiota and Serum Biochemical Markers in Asian Patients With Drug-induced Liver Injury
Who cites it
54 citing papers in PubMed, 72 citations in OpenAlex.
- Disrupted Gut Viral-Bacterial Ecology of Patients With Liver Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin deficient mice.EMBO molecular medicine · 2026Article
- Lactobacillus Acidophilus Protects against alcohol-associated Liver Disease in Mice Via Gut Microbiota Modulation and Alleviation of Inflammation and Oxidative Stress.Probiotics and antimicrobial proteins · 2026Article
- Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria.Science signaling · 2025Article
- Gut microbiome-specific nanoparticle-based therapeutics for liver diseases.World journal of gastroenterology · 2025Review
- Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.Applied microbiology and biotechnology · 2025Article
- Transcriptomic and lipidomic analysis of aging-associated inflammatory signature in mouse liver.Inflammation and regeneration · 2025Article
- From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease.Microorganisms · 2025Review
- Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.AIMS microbiology · 2025Review
- Gut Roseburia is a protective marker for peritoneal metastasis of gastric cancer.Cancer medicine · 2024Article
- The microbiota and T cells non-genetically modulate inherited phenotypes transgenerationally.Cell reports · 2024Article
- Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.Biomedicines · 2024Review
- Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Natural products for Gut-X axis: pharmacology, toxicology and microbiology in mycotoxin-caused diseases.Frontiers in pharmacology · 2024Review
- Mapping the relationship between alcohol use disorder and gut microbiota: a 20-year bibliometric study.Frontiers in microbiology · 2024Article
- Fecal cytolysin does not predict disease severity in acutely decompensated cirrhosis and acute-on-chronic liver failure.Hepatobiliary & pancreatic diseases international : HBPD INT · 2023Article
- Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury.Scientific reports · 2023Article
- Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2023Review
- L-amino acid oxidase-1 is involved in the gut-liver axis by regulating 5-aminolevulinic acid production in mice.The Journal of veterinary medical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
The intestinal microbiome plays a major role in the pathogenesis of liver disease, with a hallmark event being dysbiosis, or an imbalance of pathobionts and beneficial bacteria with the associated deleterious effects on their host. Reducing the number of intestinal bacteria with antibiotic treatment is generally advantageous in experimental liver diseases. Complete absence of intestinal microbiota as in germ-free rodents can be protective in autoimmune hepatitis and hepatic tumors induced by chemicals, or it can exacerbate disease as in acute toxic liver injury and liver fibrosis/cirrhosis. In alcoholic liver disease, nonalcoholic fatty liver disease, and autoimmune cholangiopathies, germ-free status can be associated with worsened or improved hepatic phenotype depending on the experimental model and type of rodent. Some of the unexpected outcomes can be explained by the limitations of rodents raised in a germ-free environment including a deficient immune system and an altered metabolism of lipids, cholesterol, xenobiotics/toxins, and bile acids. Given these limitations and to advance understanding of the interactions between host and intestinal microbiota, simplified model systems such as humanized gnotobiotic mice, or gnotobiotic mice monoassociated with a single bacterial strain or colonized with a defined set of microbes, are unique and useful models for investigation of liver disease in a complex ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.